About Us

Our Vision

Making Early Achievable

At NeuroSpectrum Insights (NSI) we envision a world where clinicians have the ability to uncover neurodevelopment conditions such as autism as early as possible, paving the way for timelier interventions and better patient outcomes. 

Our Mission

Transforming Neurological Assessments

NSI is committed to delivering breakthrough software technology that ultimately enhances a clinician’s ability to more precisely assess various neurodivergent people, beginning with autism and progressing to dyslexia, attention-deficit/hyperactivity disorder (ADHD), and schizophrenia.

Our Story

NeuroSpectrum Insights (NSI) is a medical device company born of the combined passions and visions of a doctor and brain pathologist, a dedicated team of clinical researchers, an autism center neurologist, several universities, and a seasoned medical industry entrepreneur. 

Pioneering research by Manual Casanova, MD,  Ayman El-Baz, PhD, Gregory Barnes, MD, and Ahmed Soliman, PhD working together with a dedicated team of bioengineers and computer scientists, produced a groundbreaking software technology. The resulting technology created the foundation for a new company. Based on the licensing of the technology from the University of Louisville during 2016 and the engagement of a seasoned medical device industry executive and entrepreneur during 2017, the company was formed. Under the leadership of Mr. Andrew D. Stewart, CEO, the NeuroSpectrum Insights mission was established to redefine early autism detection and make early, precise assessment attainable.  As this technology is being readied for marketplace entry, Dr. Casanova and Dr. Barnes remain principal advisors.

NSI envisioned and pursued a groundbreaking method of brain structure measurement that could revolutionize the identification of autism in children as young as toddlers.

In a world where the current average age of an autism diagnosis is 5 years, this advancement would be transformative for individuals with autism, their families, medical providers, caregivers, and the communities they impact. 

Through collaboration with the University of Louisville, NSI is on the cusp of delivering technology that maps and analyzes brain structures using MRI scans, advancing the detection of neurological and neurodevelopmental conditions. Our work is guided by a singular mission: to empower clinicians with innovative tools that enable timely interventions, fostering brighter futures for children and their families.

The Team

Meet the team of innovators dedicated to making our vision and mission a reality.

Visionaries

Dr. Casanova’s passion for research and understanding autism is at the very center of NeuroSpectrum Insights’ vision and mission to make early achievable. In his 2019 book Defining Autism, A Guide to Brain, Biology, and Behavior, he sets a new benchmark for understanding autism and asserts, “while there are different causes and variations of autism, there is in fact one biological autism. By examining developmental and genetic factors and investigating lesser-known autism-related syndromes, it [is possible to] clears away misconceptions surrounding this complex condition.”

Previously, Dr. Casanova belonged to the founding board of the National Alliance for Autism Research (now Autism Speaks) and the Autism Tissue Board. He has served on the Board of Directors or Scientific Advisory Board of numerous organizations (Autism Research Institute, Generation Rescue, On Mental Health, Families for Effective Autism Treatment, Clearly Present Foundation, Our Sunny World [Russia], Irlen Internation) and is presently on the editorial board of 15 different medical journals.

Honors:

  • Chairperson of the Developmental Brain Disorders Study Section
  • Physicians Recognition Award by the American Medical Association (AMA)
  • National Research Service Award by the Public Health Service (PHS)
  • The Stanley Scholars title
  • Distinguished Faculty Award by the Medical College of Georgia
  • Senior Scientist Award by the Winter Workshop on Schizophrenia
  • Title of Honorary Professor from the University of Krasnoyarsk
  • Gottfried and Gisela Kolb Endowed Chair in Outpatient Psychiatry (University of Louisville)
  • Professor of Anatomical Sciences and Neurobiology (University of Louisville) 
  • Contributing Piece Award by FEAT
  • Frontiers Spotlight Award (2018)
  • High-end Foreign Expert Award from China (2015)
  • President of the International Consortium of Autism Institutes (ICAI) (2016)
  • Plenary Speaker at the British Dyslexia Association, Cortical Evolution and both the International Congress of Autism and World Autism Congress (2018)

As a practicing neurologist specializing in autism, epilepsy, genetics, and neuropharmacology, Dr. Barnes is passionate about developing research-based solutions for the management of autism. With NSI, he is committed to delivering groundbreaking technology for earlier autism detection to clinicians, parents, and caregivers. 

Currently, he serves as Director of the Norton Children’s Austism Center at the University of Louisville. Dr. David L. Dunn, MD, Phd, Executive Vice President for Health Affairs at the University of Louisville, said of Dr. Barnes, “[He] is a national leader in providing care for people who are affected by autism. His emphasis on evidence-based treatment, teamed with his research into potential genetic influences into the development of the disorder, as well as the potential influence into epilepsy, make him a perfect fit as the inaugural permanent Director of the University of Louisville Autism Center.”

Honors:

  • Appointment as National Neurology Co-leader for the Autism Treatment Network (2008)
  • Appointment to the external Scientific Advisory Committee for the Preclinical Autism Consortium for Therapeutics (PACT) (2012)
  • Reviewer for the Autism Speaks special grant program for preclinical translational research and the Autism Speaks translational postdoctoral fellowship grant program. 
  • The Spafford Ackerly Chair for Child and Adolescent Psychiatry
  • Faculty member as Associate Professor of Neurology and Pediatrics at the University of Louisville
  • Prior academic appointments at Washington University School of Medicine in St. Louis, Harvard Medical School, Duke University Medical School, the University of Kentucky College of Medicine, and Vanderbilt School of Medicine

Leadership Team

Mark Rosenberg, MD
Chairman of the Board of Directors

Dr. Rosenberg brings 45 years of diverse experience in hospital and clinical leadership, business ventures and innovation, and leadership roles within the American College of Emergency Physicians (ACEP). During the Covid pandemic, Dr. Rosenberg had the privilege of serving as President of ACEP, where he represented over 40,000 emergency physicians. He is well known for his medical career as an emergency physician and Chairman of Emergency Medicine at a prestigious teaching hospital in New Jersey. 

Andrew Stewart
Chief Executive Officer

Mr. Stewart brings over 45 years of experience in the medical device industry. He has served as CEO of NSI and its predecessor Autism Diagnosis Technology since May 2017. Previously, he held the position of CEO for Wipe-Rite Technologies, Inc. and Medeject, Inc., both medical device startups. From 2006 to 2013 he was CEO of EyeTect, LLC, a startup medical device company focused on eye tracking for diagnosing depth of consciousness monitoring.

Joerg H. Klaube
Chief Financial Officer

Mr. Klaube‘s career encompasses a broad range of appointments in corporate financial management, controllership, and administrative functions in a variety of business environments, including publicly held companies. From 2013 to 2017 he held the position of Chief Financial Officer at Turnpoint Medical Devices Inc., a designer and marketer of specialized infusion pumps, and in 2018 he joined NSI. 

John Paulson, PhD
Regulatory and Clinical Affairs Advisor

Dr. Paulson brings 25 years of experience with Johnson & Johnson, where he held the position of Vice President of Regulatory and Clinical Affairs. He conducted all regulatory and QA due diligence for a large medical device company within J&J, resulting in several large acquisitions, divestitures, and equity projects

Boura Ali
Director

Mr. Ali combines over 19 years of experience in the pharmacy industry and as an entrepreneur working in the retail and hospital industries. He has advised fortune 100 companies on logistics, international marketing, and new technology.

Jason Pottinger
Director

Mr. Pottinger has over 10 years of combined experience in technology commercialization in senior management positions following a 9-year career as a real estate investor and professional athlete. Previously, he worked with Plasma Stream Technologies and Predictive Aviation Analytics.

Corey Park
Director

Mr. Park brings value to companies by identifying and utilizing leverage, building momentum in their marketplace, and positioning the entities to maximize strategic resource and capital channels within the private and public markets. As a strategic thinker and avid student of leading-edge business strategy, he provides high-level consultation on every aspect of the business. 

Michael Thomas
Marketing Director

Mr. Thomas brings 20 years of professional healthcare marketing, market development, and financial management experience gained within the Johnson & Johnson Family of Companies. To this he adds the hands-on experiences of assisting clients of the two healthcare consulting companies he has founded. He focuses on marketing research, strategic marketing planning, effective communications execution, and results measurement across the array of professional healthcare industry segments. His dedication to the fundamentals of marketing as well as its emerging principles and tools gives him the perspective to deliver superior marketing results.

Phil Sheehy
Director of Operation

Mr. Sheehy brings over 25 years of experience in all aspects of business development in the software industry. Beginning his career with IBM mainframe system software and computer telephony solutions, he has spent the last 15 years helping early and growth stage companies drive revenue and execute innovative Go-To-Market sales, marketing, and business development strategies.

Timeline

October 2024
Unveiling

NSI unveils its recently developed company identity and branding suite.

June 2024
“Ground Truth” Evaluation

NSI, in collaboration with the software engineering leader Innolitics, launches an autism focused “ground truth” evaluation to prepare for its FDA clearance submission later this year.

February 2023
Name Change

The investigational company Autism Diagnostic Technologies, Inc. changes its name to NeuroSpectrum Insights, Inc. (NSI) to more accurately reflect its comprehensive vision, mission, and commercialization objectives.

December 2023
Ramping Up

Following a seven-year exploration of a breakthrough technology for assessing neurological and neurodevelopmental disorders, Autism Diagnostic Technologies, Inc. begins ramping up for the commercialization of the technology.

May 2017
New Leadership

Andrew Stewart tapped as CEO of NeuroSpectrum Insights.

October 2016
Founding

Our technology licensed for commercial use. Read more about the technology.